BioSpecifics Technologies
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1401 Sterrett St, Houston, Texas, 77002,...Phone Number
(516) 593-7000Website
www.biospecifics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About BioSpecifics Technologies
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytrens contracture and Peyronies disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in LynRead more
BioSpecifics Technologies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioSpecifics Technologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if BioSpecifics Technologies is spiking on competitors!
Earning: See what the market has to say on BioSpecifics Technologies recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at BioSpecifics Technologies
BioSpecifics Technologies, which may be a good buyer, showed buying intent in Masked Content Topic
Check if BioSpecifics Technologies has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when BioSpecifics Technologies launches new products
Funding: Get notified immidiatlly once BioSpecifics Technologies has new funding data
Click to see if BioSpecifics Technologies had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to BioSpecifics Technologies
Compare insights from companies similar to BioSpecifics Technologies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioSpecifics Technologies is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioSpecifics Technologies is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioSpecifics Technologies.
BioSpecifics Technologies Tech Stack
A closer look at the technologies used by BioSpecifics Technologies
Most Recent Scoops
Left Company
Executive Move
Mergers & Acquisitions (M&A)
Promotion
Executive Move
Earnings
Earnings
BioSpecifics Technologies News & Media
Endo Completes Acquisition of BioSpecifics
DUBLIN, Dec. 2, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that it completed the previously announced acquisition of BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, for $88.50 per share in an all-cash transaction, for an...Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer
DUBLIN, Nov. 18, 2020 /PRNewswire/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), in connection with the previously announced tender...BioSpecifics Merger Investigation: Halper Sadeh LLP Encourages BioSpecifics Technologies Corp. Shareholders to Contact the Firm – BSTC
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating BioSpecifics Technologies Corp. (NASDAQ: BSTC) and its board of directors for possible breaches of fiduciary duty and other violations of the federal securities laws concerning the sale of BioSpecifics to Endo International plc.Lifshitz Law Firm, P.C. Announces Investigation of BioSpecifics Technologies Corp., Cleveland BioLabs, Inc., Concho Resources Inc., CONSOL Energy Inc., CONSOL Coal Resources LP, Endurance International Group Holdings, Inc., GCI Liberty, Inc., Liberty Broadband Corporation, and PNM Resources, Inc.
NEW YORK, Nov. 11, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of BSTC to Endo International plc for $88.50 per share. If you are a BSTC investor,...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioSpecifics Technologies
Sign Up For FreeTo access detailed company insights
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytrens contracture and Peyronies disease under the XIAFLEX brand in Canada and Australia, as... Read More
